Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study on Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps and Eosinophilic Otitis Media

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying the effects of a medication called Dupilumab on patients who have two specific conditions: chronic rhinosinusitis with nasal polyps and eosinophilic otitis media. Chronic rhinosinusitis with nasal polyps is a long-term inflammation of the sinuses that leads to the growth of polyps, which are small, non-cancerous swellings. Eosinophilic otitis media is a type of ear inflammation characterized by the presence of a high number of eosinophils, which are a type of white blood cell. The medication being tested, Dupilumab, is administered as a solution for injection using a pre-filled pen.

The purpose of this study is to understand how Dupilumab affects ear symptoms and hearing function in patients with these conditions. Participants in the study will receive Dupilumab through subcutaneous injection, which means the medication is injected under the skin. The study will observe changes in symptoms and hearing over a period of time, specifically looking at how these change from the start of the treatment to 6 or 12 months later. Participants will be asked to complete questionnaires about their symptoms and undergo hearing tests to track any improvements or changes.

Throughout the study, researchers will monitor the participants' progress by comparing their initial condition with their condition after receiving Dupilumab for several months. This will help determine the effectiveness of the treatment in managing symptoms related to chronic rhinosinusitis with nasal polyps and eosinophilic otitis media. The study aims to provide valuable insights into how Dupilumab can potentially improve the quality of life for individuals suffering from these conditions.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initiation of treatment

    Begin treatment with Dupixent, which contains the active substance dupilumab.

    The medication is administered as a subcutaneous injection using a pre-filled pen.

    The dosage is 300 mg per injection.

  2. Step 2

    Baseline assessment

    Complete initial assessments, including otologic questionnaires to evaluate ear symptoms and auditory function.

    These assessments establish a baseline for future comparisons.

  3. Step 3

    Ongoing treatment and assessments

    Continue receiving Dupixent injections as part of regular clinical care.

    Assessments will be conducted at 1, 3, 6, and 12 months to monitor changes in questionnaire scores, audiometry outcomes, and otoscopic findings.

    The primary focus is on changes between baseline and 6 or 12 months of treatment.

  4. Step 4

    Completion of study

    The study is expected to conclude by October 2, 2027.

    Final assessments will be compared to baseline data to determine the effect of dupilumab on ear symptoms and auditory function.

Who can join the trial?

6 criteria

  • Patients must have **chronic rhinosinusitis with nasal polyps** and **eosinophilic otitis media**. These are conditions that affect the nose and ears.
  • For the retrospective part of the study, patients should have started **dupilumab** treatment from 2020 onwards. Dupilumab is a medication used to treat certain conditions.
  • Patients must have enough data available to meet the main goal of the study, which includes completing specific ear-related questionnaires at the start and after at least 6 or 12 months of treatment.
  • For the prospective part of the study, patients must be adults, meaning they are 18 years or older, and are starting dupilumab treatment as part of their regular medical care.
  • Both men and women can participate in the study.
  • The study does not include vulnerable populations, which means it does not involve groups that might need special protection.

Who cannot join the trial?

3 criteria

  • Patients who do not have chronic rhinosinusitis with nasal polyps or eosinophilic otitis media cannot participate. These are specific conditions related to inflammation in the nose and ears.
  • Patients who are not within the specified age range cannot participate. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population cannot participate. This means people who might need special protection or care.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

  • Verified

    Amsterdam UMC

    The NetherlandsAmsterdam, The Netherlands

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Dupilumab is a medication used in this clinical trial to treat patients with chronic rhinosinusitis with nasal polyps and eosinophilic otitis media. It works by blocking certain proteins in the body that can cause inflammation, helping to reduce symptoms such as nasal congestion and improve ear function.

What is already known about the treatment

Dupilumab – Dupilumab is administered as an injection under the skin, typically in the upper arm, thigh, or abdomen. It is currently approved and widely used in medical practice, with ongoing research to explore its full potential. The main therapeutic indications for dupilumab include chronic rhinosinusitis with nasal polyps and eosinophilic otitis media. At the molecular level, dupilumab works by blocking the signaling of certain proteins involved in inflammation, specifically interleukin-4 and interleukin-13, which are key drivers of allergic reactions and inflammation. It is classified as a monoclonal antibody, a type of biologic medication that targets specific pathways in the immune system.

Investigated diseases

  • Chronic Rhinosinusitis with Nasal Polyps

    This condition involves long-term inflammation of the sinuses and nasal passages, often accompanied by the growth of polyps. These polyps are non-cancerous swellings that can obstruct nasal airflow and lead to breathing difficulties. Symptoms may include nasal congestion, reduced sense of smell, and facial pressure or pain. The condition can persist for months or even years, with symptoms fluctuating in severity. It is often associated with other respiratory conditions, such as asthma. The exact cause is not fully understood, but it may involve a combination of genetic and environmental factors.

  • Eosinophilic Otitis Media

    This is a type of ear inflammation characterized by the presence of a high number of eosinophils, a type of white blood cell, in the middle ear. It often occurs in individuals with asthma or nasal polyps and can lead to persistent ear infections. Symptoms may include ear pain, hearing loss, and a feeling of fullness in the ear. The condition can be chronic, with symptoms that may worsen over time. It is thought to be related to an underlying allergic or immune response. The exact mechanisms and triggers are still being studied.

Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2023-508068-31-00Estimated enrolment50 patientsSponsorAmsterdam UMC

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).